InflaRx to host conference call today at 8:30 am EDT / 2:30 pm CEST JENA, Germany, Oct. 27, 2021 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing ...
Pyoderma Gangraenosum is a debilitating, rare autoimmune disease marked by large, painful skin ulcers JENA, Germany, June 13, 2019 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), an innovative ...
Interim results will be available by the end of 2021 with final results expected in 2022 Initial positive data from the first 5 patients previously announced in Q1 2020 JENA, Germany, April 15, 2021 ...
Darin hatten 13 Patienten mit Pyoderma gangraenosum (Dermatitis ulcerosa) randomisiert und doppelblind eine einmalige Infusion mit 5 mg/kg des TNF-alpha-Blockers Infliximab (Remicade®) erhalten. 17 ...
Third autoimmune disease being evaluated with IFX-1 Pyoderma Gangraenosum is a debilitating, rare autoimmune disease marked by large, painful ulcers JENA, Germany, Feb. 27, 2019 (GLOBE NEWSWIRE) -- ...
Der Anruf kommt aus einer Aachener Klinik. Die Stimme am Telefon klingt schwach. Doch dann schwingt Freude mit übers Wiedererkennen und Erinnern an ihre Geschichte, die wir im vorigen Sommer in ...
JENA, Deutschland - InflaRx N.V. (NASDAQ:IFRX) hat laut einer Pressemitteilung die mündliche Präsentation von Phase-III-Studienergebnissen für Vilobelimab bei Pyoderma gangraenosum im Rahmen der "Late ...
Ein 72-jähriger Patient stellte sich in unserer Klinik mit seit zehn Jahren rezidivierenden Ulzerationen am rechten Gaumenbogen vor. In der Vergangenheit war eine Exzision der Läsion erfolgt, die ein ...
Four out of 10 evaluable patients showed clinical response (PGA score ≤ 3), three of whom achieved complete closure of target lesion Treatment was well tolerated; no adverse events associated with ...
Target enrollment of 18 patients reached across three different dose groups Interim results will be available by the end of 2021 with final results expected in 2022 Initial positive data from the ...
InflaRx to host conference call today at 8:30 am EDT / 2:30 pm CEST JENA, Germany, Oct. 27, 2021 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing ...
JENA, Germany, Oct. 27, 2021 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results